<DOC>
	<DOCNO>NCT01554176</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy filorexant ( MK-6096 ) versus placebo adjunctive treatment major depressive disorder ( MDD ) , participant partial responder antidepressant monotherapy one identify selective serotonin reuptake inhibitor ( SSRIs ) serotonin norepinephrine reuptake inhibitor ( SNRIs ) , bupropion . The primary hypothesis study filorexant superior placebo augmentation therapy respect change baseline Week 6 Montgomery Asberg Depression Rating Scale ( MADRS ) total score .</brief_summary>
	<brief_title>Safety Efficacy MK-6096 Adjunctive Therapy Participants With Major Depressive Disorder And Partial Response Antidepressant Monotherapy ( MK-6096-022 )</brief_title>
	<detailed_description>Participants continue take pretrial antidepressant medication prescribe throughout trial . Participants randomize 1:1 ratio receive filorexant placebo 6-week treatment period . Following completion treatment period , participant enter 2-week double-blind run-out period . During run-out period , participant receive placebo 6-week treatment period continue receive placebo participant receive filorexant 6-week treatment period randomize receive either filorexant placebo 1:1 ratio .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Participant ( ) male ( b ) female reproductive potential , ( c ) female reproductive potential serum betahCG level consistent nongravid state screening agrees use acceptable contraception ; Current primary diagnosis recurrent major depressive disorder , without psychotic feature , current moderate severe depressive episode ; Duration current major depressive episode must least 2 month 18 month Screening ; Participant undergone adequate trial antidepressant ( one identify SSRIs SNRIs , bupropion ) current depressive episode . Key Current primary psychiatric diagnosis major depression ; Lifetime diagnosis bipolar disorder , schizophrenia , schizoaffective disorder , psychotic disorder ; Alcohol substance abuse dependence ( exclude nicotine ) ; Clinically significant abnormality disease central nervous system ( include dementia cognitive disorder traumatic brain injury ) ; Imminent risk selfharm harm others ; Participant psychiatric inpatient ; Participant continuous antidepressant treatment &gt; 18 month prior Screening visit ; Inadequate response 3 adequate antidepressant trial ( include current antidepressant treatment trial ) treatment current depressive episode ; Participant ever receive electroconvulsive therapy , transcranial magnetic stimulation , vagal nerve stimulation treatment depression ; History narcolepsy , cataplexy , circadian rhythm disorder , parasomnia , sleeprelated breathe disorder , restless legs syndrome , periodic limb movement disorder , excessive daytime sleepiness difficulty sleep due medical condition ; Clinical , laboratory , electrocardiogram ( ECG ) evidence significant systemic disease ; Cardiovascular event ( e.g. , myocardial infarction ) procedure ( e.g. , coronary artery bypass surgery ) within 3 month study ; History malignancy â‰¤5 year prior study , except adequately treat basal cell squamous cell skin cancer situ cervical cancer ; Body Mass Index &gt; 40 kg/m^2 ; Pregnancy , breastfeeding , expect become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Current depressive episode</keyword>
	<keyword>moderate severe</keyword>
</DOC>